Rigel Pharmaceuticals, Inc. (RIGL)

Market Cap	428.22M
Revenue (ttm)	157.37M
Net Income (ttm)	3.88M
Shares Out	17.62M
EPS (ttm)	0.22
PE Ratio	109.79
Forward PE	25.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,437
Open	23.92
Previous Close	23.91
Day's Range	23.46 - 24.58
52-Week Range	7.48 - 29.82
Beta	0.95
Analysts	Buy
Price Target	31.30 (+28.75%)
Earnings Date	Nov 7, 2024

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 29, 2000
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: RIGL
• Website: https://www.rigel.com

Financial Performance

In 2023, Rigel Pharmaceuticals's revenue was $115.78 million, an increase of 0.03% compared to the previous year's $115.74 million. Losses were -$25.09 million, -57.16% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price forecast is $31.3, which is an increase of 28.75% from the latest price.

Price Target

$31.3

(28.75% upside)

Analyst Consensus: Buy